Nayoung Sung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nayoung Sung has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Joanne Kwak-Kim
Reproductive Medicine and Immunology, Obstetrics and Gynecology, Clinical Sciences Department, Chicago Medical School, Rosalind Franklin University of Medicine and Science
13 shared publications Li Wu
Reproductive Medicine, Department of Obstetrics and Gynecology, Chicago Medical School at Rosalind Franklin University of Medicine and Science, Vernon Hills, IL, USA
6 shared publications- Svetlana Dambaeva
Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA
6 shared publications - Alice Gilman-Sachs
Clinical Immunology Laboratory Rosalind Franklin University of Medicine and Science North Chicago IL USA
5 shared publications - Annie Skariah
Reproductive Medicine and Immunology, Department of Obstetrics and Gynecology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois
5 shared publications Kenneth Beaman
5 shared publications
Latest Publications
- 29 January 2021
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 85 (4) , e13395
A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses
Over the last few decades, the advancement in reproductive technologies and protocols to improve embryo quality through culture techniques and genetic testing to eliminate chromosomally abnormal embryos resulted in better pregnancy rates and outcomes after fertility treatments. Unfortunately, some patients still struggle with recurrent implantation failures (RIFs) and recurrent pregnancy losses (RPLs). Immune etiologies have been attributed to play an important role in some of those patients. Maintaining a pre‐conceptional anti‐inflammatory environment for implantation and pregnancy continuation yields superior results. Intravenous immunoglobulin G (IVIG) treatment has been reported to enhance reproductive outcome in patients with RIF and RPL with immune dysregulations. In this systemic review, we analyzed outcomes of IVIG trials for RIF and RPL, its mechanism of action, dosing, administration, side‐effects, and evidence for its use in women with RIF and RPL.
- 29 January 2021
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 85 (4) , e13395
A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses
Over the last few decades, the advancement in reproductive technologies and protocols to improve embryo quality through culture techniques and genetic testing to eliminate chromosomally abnormal embryos resulted in better pregnancy rates and outcomes after fertility treatments. Unfortunately, some patients still struggle with recurrent implantation failures (RIFs) and recurrent pregnancy losses (RPLs). Immune etiologies have been attributed to play an important role in some of those patients. Maintaining a pre‐conceptional anti‐inflammatory environment for implantation and pregnancy continuation yields superior results. Intravenous immunoglobulin G (IVIG) treatment has been reported to enhance reproductive outcome in patients with RIF and RPL with immune dysregulations. In this systemic review, we analyzed outcomes of IVIG trials for RIF and RPL, its mechanism of action, dosing, administration, side‐effects, and evidence for its use in women with RIF and RPL.
- 21 February 2020
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 83 (5) , e13230
PD‐1 and PD‐L1 expression on T‐cell subsets in women with unexplained recurrent pregnancy losses
Problem: Does programmed death‐1 (PD‐1)/programmed death ligand‐1 (PD‐L1) expression on the T‐cell subsets such as T helper (Th) 1, Th17, and Treg cells differentiate women with recurrent pregnancy losses (RPL) from normal fertile women?Method of study: The study was designed as a prospective cohort study. Forty‐five women with two or more RPL of unknown etiology and twenty fertile women who had at least one or more live‐born infants were enrolled prospectively from Jan 2017 to Jul 2019. PD‐1 and PD‐L1 expression on T‐cell subsets were measured by flow cytometric analysis.Results: The proportions of PD‐1+ Th1 (CD4+/IFN‐γ+/CD279+ and CD4+/TNF‐α+/CD279+) and PD‐1+ Th17 cells (CD4+/IL17+/CD279+) were significantly lower in RPL group than those of controls (P < .05, respectively). The proportion of PD‐1+ Tregs (CD4+/CD25+/CD127dim/−/CD279+) in RPL group was not different from that of controls. The proportion of PD‐L1+ Th17 cells (CD4+IL17+CD274+) was significantly lower as compared with that of /controls (P < .05). However, the proportions of PD‐L1+ Th1 (CD4+/IFN‐γ+/CD274+ and CD4+/TNF‐α+/CD274+) and PD‐L1+ Treg (CD4+/CD25+/CD127dim/−/CD274+) cells were not different between the RPL group and controls (P > .05, respectively). In Th1, Th17 and Treg cells, the proportions of PD‐L1+ (CD274+) cells were significantly higher than those of PD‐1+ (CD279+) cells in both RPL group and controls (P < .05, respectively).Conclusion: PD‐1 and PD‐L1 expressions on Th17 cells as well as PD‐1 expression on Th1 cells were significantly downregulated in women with RPL, which may lead to increased Th1 and Th17 immunity, and imbalance between Th17, Th1, and Treg cells in women with RPL.
- 21 February 2020
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 83 (5) , e13230
PD‐1 and PD‐L1 expression on T‐cell subsets in women with unexplained recurrent pregnancy losses
Problem: Does programmed death‐1 (PD‐1)/programmed death ligand‐1 (PD‐L1) expression on the T‐cell subsets such as T helper (Th) 1, Th17, and Treg cells differentiate women with recurrent pregnancy losses (RPL) from normal fertile women?Method of study: The study was designed as a prospective cohort study. Forty‐five women with two or more RPL of unknown etiology and twenty fertile women who had at least one or more live‐born infants were enrolled prospectively from Jan 2017 to Jul 2019. PD‐1 and PD‐L1 expression on T‐cell subsets were measured by flow cytometric analysis.Results: The proportions of PD‐1+ Th1 (CD4+/IFN‐γ+/CD279+ and CD4+/TNF‐α+/CD279+) and PD‐1+ Th17 cells (CD4+/IL17+/CD279+) were significantly lower in RPL group than those of controls (P < .05, respectively). The proportion of PD‐1+ Tregs (CD4+/CD25+/CD127dim/−/CD279+) in RPL group was not different from that of controls. The proportion of PD‐L1+ Th17 cells (CD4+IL17+CD274+) was significantly lower as compared with that of /controls (P < .05). However, the proportions of PD‐L1+ Th1 (CD4+/IFN‐γ+/CD274+ and CD4+/TNF‐α+/CD274+) and PD‐L1+ Treg (CD4+/CD25+/CD127dim/−/CD274+) cells were not different between the RPL group and controls (P > .05, respectively). In Th1, Th17 and Treg cells, the proportions of PD‐L1+ (CD274+) cells were significantly higher than those of PD‐1+ (CD279+) cells in both RPL group and controls (P < .05, respectively).Conclusion: PD‐1 and PD‐L1 expressions on Th17 cells as well as PD‐1 expression on Th1 cells were significantly downregulated in women with RPL, which may lead to increased Th1 and Th17 immunity, and imbalance between Th17, Th1, and Treg cells in women with RPL.
- Open Access
- 1 January 2018
- Published by Korean Society of Obstetrics and Gynecology in Obstetrics & Gynecology Science
- Vol. 61 (1) , 79-87
Cosmetic outcomes of cesarean section scar; subcuticular suture versus intradermal buried suture
Yang J, et al. Obstet Gynecol Sci. 2018 Jan;61(1):79-87. https://doi.org/10.5468/ogs.2018.61.1.79
- 1 January 2018
- Published by Korean Society of Obstetrics and Gynecology in Obstetrics & Gynecology Science
- Vol. 61 (1) , 79-87
Open AccessCosmetic outcomes of cesarean section scar; subcuticular suture versus intradermal buried suture
Yang J, et al. Obstet Gynecol Sci. 2018 Jan;61(1):79-87. https://doi.org/10.5468/ogs.2018.61.1.79
- 27 February 2017
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 77 (6)
Low‐dose prednisone and immunoglobulin G treatment for woman at risk for neonatal alloimmune thrombocytopenia and T helper 1 immunity
Problem: Fetal and neonatal alloimmune thrombocytopenia is an alloimmune disorder resulting from platelet opsonization by maternal antibodies that destroy fetal platelets. As there is no antenatal screening or immunization to prevent sensitization, selection of high‐risk population or the prevention of antenatal sensitization is significantly limited.Method of study: (i) A case report of ante‐ and postnatal management of a woman with paternal homozygosity for human platelet antigen‐1(HPA) incompatibility. (ii) A retrospective case‐control study of 11 confirmed FNAIT patients, 8 possible‐FNAIT women, and 10 women with confirmed ITP.Result: Antenatal screening, prevention of maternal sensitization by serial monitoring and immunosuppression with prednisone and intravenous immunoglobulin G (IVIG) infusion resulted in two successful pregnancies without sensitization.Conclusion: Screening for couples at risk and prednisone and/or IVIG treatment is an option for women with paternal homozygosity for offending HPA antigen to prevent antenatal sensitization. HPA incompatibility is associated with increased Th1 immunity and NK cell cytotoxicity.
- 27 February 2017
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 77 (6)
Low‐dose prednisone and immunoglobulin G treatment for woman at risk for neonatal alloimmune thrombocytopenia and T helper 1 immunity
Problem: Fetal and neonatal alloimmune thrombocytopenia is an alloimmune disorder resulting from platelet opsonization by maternal antibodies that destroy fetal platelets. As there is no antenatal screening or immunization to prevent sensitization, selection of high‐risk population or the prevention of antenatal sensitization is significantly limited.Method of study: (i) A case report of ante‐ and postnatal management of a woman with paternal homozygosity for human platelet antigen‐1(HPA) incompatibility. (ii) A retrospective case‐control study of 11 confirmed FNAIT patients, 8 possible‐FNAIT women, and 10 women with confirmed ITP.Result: Antenatal screening, prevention of maternal sensitization by serial monitoring and immunosuppression with prednisone and intravenous immunoglobulin G (IVIG) infusion resulted in two successful pregnancies without sensitization.Conclusion: Screening for couples at risk and prednisone and/or IVIG treatment is an option for women with paternal homozygosity for offending HPA antigen to prevent antenatal sensitization. HPA incompatibility is associated with increased Th1 immunity and NK cell cytotoxicity.
- Open Access
- 1 January 2017
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 44 (2) , 111-117
Predictors of live birth and pregnancy success after in vitro fertilization in infertile women aged 40 and over
Kim HO, et al. Clin Exp Reprod Med. 2017 Jun;44(2):111-117. https://doi.org/10.5653/cerm.2017.44.2.111
- 1 January 2017
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 44 (2) , 111-117
Open AccessPredictors of live birth and pregnancy success after in vitro fertilization in infertile women aged 40 and over
Kim HO, et al. Clin Exp Reprod Med. 2017 Jun;44(2):111-117. https://doi.org/10.5653/cerm.2017.44.2.111
- Open Access
- 1 January 2017
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 44 (1) , 1-7
Intravenous immunoglobulin G in women with reproductive failure: The Korean Society for Reproductive Immunology practice guidelines
Sung N, et al. Clin Exp Reprod Med. 2017 Mar;44(1):1-7. https://doi.org/10.5653/cerm.2017.44.1.1
- 1 January 2017
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 44 (1) , 1-7
Open AccessIntravenous immunoglobulin G in women with reproductive failure: The Korean Society for Reproductive Immunology practice guidelines
Sung N, et al. Clin Exp Reprod Med. 2017 Mar;44(1):1-7. https://doi.org/10.5653/cerm.2017.44.1.1
- 1 November 2016
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 118, 70-75
Deficiency in memory B cell compartment in a patient with infertility and recurrent pregnancy losses
- 1 November 2016
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 118, 70-75
Deficiency in memory B cell compartment in a patient with infertility and recurrent pregnancy losses
- 1 October 2016
- Published by Elsevier in Autoimmunity Reviews
- Vol. 15 (10) , 943-947
Humoral and cellular autoimmunity in women with recurrent pregnancy losses and repeated implantation failures: A possible role of vitamin D
- 1 October 2016
- Published by Elsevier in Autoimmunity Reviews
- Vol. 15 (10) , 943-947
Humoral and cellular autoimmunity in women with recurrent pregnancy losses and repeated implantation failures: A possible role of vitamin D
- 12 June 2016
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 76 (1) , 50-58
Gonadotropin‐releasing hormone analogues lead to pro‐inflammatory changes in T lymphocytes
Problem: We aimed to investigate the effect of gonadotropin‐releasing hormone (GnRH) analogues on T‐cell immunity.Method of study: TNF‐α+‐, INF‐ɣ+‐, IL‐10+‐, and IL‐17+‐expressing T cells in peripheral blood mononuclear cells (PBMCs) were treated with various concentrations (0.1, 1, 5, and 10 μm) of GnRH agonist (buserelin acetate) and antagonist (cetrorelix acetate) for 4 hours in vitro and they were analyzed with flow cytometry.Results: TNF‐α+/IL‐10+ T helper (TH) cell ratios were increased in PBMCs treated with 1, 5, and 10 μm GnRH agonist when compared to controls (P=.006, P=.014 and P=.030, respectively). IFN‐ɣ+/IL‐10+ TH cell ratios were significantly increased with 0.1, 1, 5, and 10 μm GnRH agonist as compared with controls (P=.046, P=.004, P=.013, and P=.011, respectively). TNF‐α+ TH cell levels, and IFN‐γ+/IL‐10+ TH cell ratios were significantly different (P<.001 and P<.004, respectively) between GnRH agonist‐ and antagonist‐treated cells.Conclusion: GnRH analogues induce pro‐inflammatory TH1 shift in T‐cell immunity, in vitro. GnRH treatment during assisted reproductive technology cycle might explain a possible cause of inflammatory flare in women with inflammatory conditions.
- 12 June 2016
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 76 (1) , 50-58
Gonadotropin‐releasing hormone analogues lead to pro‐inflammatory changes in T lymphocytes
Problem: We aimed to investigate the effect of gonadotropin‐releasing hormone (GnRH) analogues on T‐cell immunity.Method of study: TNF‐α+‐, INF‐ɣ+‐, IL‐10+‐, and IL‐17+‐expressing T cells in peripheral blood mononuclear cells (PBMCs) were treated with various concentrations (0.1, 1, 5, and 10 μm) of GnRH agonist (buserelin acetate) and antagonist (cetrorelix acetate) for 4 hours in vitro and they were analyzed with flow cytometry.Results: TNF‐α+/IL‐10+ T helper (TH) cell ratios were increased in PBMCs treated with 1, 5, and 10 μm GnRH agonist when compared to controls (P=.006, P=.014 and P=.030, respectively). IFN‐ɣ+/IL‐10+ TH cell ratios were significantly increased with 0.1, 1, 5, and 10 μm GnRH agonist as compared with controls (P=.046, P=.004, P=.013, and P=.011, respectively). TNF‐α+ TH cell levels, and IFN‐γ+/IL‐10+ TH cell ratios were significantly different (P<.001 and P<.004, respectively) between GnRH agonist‐ and antagonist‐treated cells.Conclusion: GnRH analogues induce pro‐inflammatory TH1 shift in T‐cell immunity, in vitro. GnRH treatment during assisted reproductive technology cycle might explain a possible cause of inflammatory flare in women with inflammatory conditions.